GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » 3-Year FCF Growth Rate

Enveric Biosciences (Enveric Biosciences) 3-Year FCF Growth Rate : 42.40% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences 3-Year FCF Growth Rate?

Enveric Biosciences's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.77.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 42.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 58.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 36.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Enveric Biosciences was 66.60% per year. The lowest was -123.30% per year. And the median was 36.70% per year.


Competitive Comparison of Enveric Biosciences's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Enveric Biosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's 3-Year FCF Growth Rate falls into.



Enveric Biosciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Enveric Biosciences  (NAS:ENVB) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Enveric Biosciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences (Enveric Biosciences) Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Executives
Frank Pasqualone director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney officer: Chief Financial Officer 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey officer: Chief Financial Officer 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil director C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson director 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel officer: Chief Technical Officer 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker director, officer: Chief Executive Officer 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini officer: Chief Scientific Officer 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward officer: Chief Financial Officer 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind director
Marcus Schabacker director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer director 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson director, officer: CEO and Chairman C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins officer: Chief Medical Officer C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103

Enveric Biosciences (Enveric Biosciences) Headlines

From GuruFocus